Cannasat batting hot streak in its CNS turnaround

First time up to bat, Anthony Giovinazzo hit what he calls a triple.  He followed that up with a single.  Now, he’s looking to park one in the bleachers. Newly installed in the executive suite at Cannasat Therapeutics (TSX-V:CTH) last November, Mr. Giovinazzo’s mandate is to rebrand the company, founded in 2004 by Moses Znaimer [...]

IntelGenx and Cannasat in Relivar licensing pact

IntelGenx (TSX-V:IGX) and Cannasat Therapeutics (TSX-V:CTH) have entered into a letter of intent that would give IntelGenx a 50% ownership stake and an exclusive worldwide licence to develop and commercialize Cannasat’s Relivar drug candidate. Under the accord, the two companies will negotiate an exclusive worldwide licence that should result in IntelGenx assuming sole product development [...]